GlassScriptPhysician profile
Crista Crowdy
NPI 1629386685
$3,266.77
in general payments reported to CMS, 2019-2025
31 companies · $748 in 2025
The $748 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $765 · 2022: $585 · 2023: $335 · 2024: $832 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $535.79 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $377.93 | 2021-2025 | Airsupra, Farxiga |
| Abbvie INC. | $310.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $232.68 | 2021-2024 | |
| Glaxosmithkline, LLC. | $229.67 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $161.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $150.47 | 2021-2024 | Verquvo, Belsomra, Lagevrio |
| Lilly USA, LLC | $149.71 | 2021-2025 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $133.51 | 2021-2025 | |
| Astellas Pharma US INC | $114.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $78.06 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.63 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $75.59 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $68.55 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $63.97 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $61.84 | 2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.96 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Verona Pharma, INC. | $46.86 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $41.54 | 2021-2025 | |
| Amgen INC. | $39.14 | 2021 | |
| Sumitomo Pharma America, INC. | $38.81 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $38.49 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.83 | 2021-2022 | |
| Daiichi Sankyo INC. | $36.61 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $25.19 | 2024 | Ingrezza |
| Philips North America LLC | $17.40 | 2025 | Vest Therapy Und |
| Bioventus LLC | $17.01 | 2025 | Exogen Ultrasound Bone Healing System |
| Idorsia Pharmaceuticals US INC | $14.28 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $13.93 | 2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $12.79 | 2022 | |
| Dexcom, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crista Crowdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.